EyePoint, Inc. (EYPT) Stock Analysis
EyePoint, Inc.
▾ What's in the 42/100 risk score? (higher = riskier)
Contributions (weight × component score) sum to the total. This near-term score now includes fundamental health (leverage, FCF trend). It excludes the Altman Z score, whose retained-earnings input this filer does not report separately. See the Financial Health section for the full balance-sheet read.
How to read EYPT (pre-profit growth)
This company is reinvesting instead of generating profit, so a standard DCF cannot price it. The useful question is whether the growth the market is paying for is achievable — and whether the company can fund itself until then.
-
1
Reverse-DCF — the growth the price demands ↓
It shows exactly how fast the business must grow to justify today's price. Compare that to what comparable companies have actually achieved.
-
2
Cash runway ↓
Can it reach profitability before it has to raise money and dilute shareholders?
-
3
Interactive calculator ↓
Set your own growth + margin assumptions and see what the business would be worth if you are right.
Standard DCF doesn't fit EYPT well — but that's expected for this kind of business. The Rule of 40 (Pre-Profit Growth) Lens below uses the metrics actually used by analysts who value laboratory analytical instruments. Reverse DCF + Football Field also work as cross-checks.
Quality & solvency checks
Cheap stocks can be cheap for a reason. These screens warn when a low valuation comes paired with structural fragility.
Why it matters: Cheap-looking stocks (low P/E or P/B) often have low Z-scores because the market knows the company is dying. Z-score warns you before you fall into a value trap.
Reference: > 3.0 = safe zone · 1.81–3.0 = grey zone · < 1.81 = distress zone
Full explanation →
The Z-score needs working capital, retained earnings, EBIT, sales and total assets from the latest balance sheet, and at least one of those isn't reported in machine-readable form here — common for foreign private issuers. We leave it blank rather than compute a distress verdict from an estimated input. It doesn't affect the reported figures in the financial tables below.
▾ The checks — what passed, what didn't (and what we couldn't measure)
-
✗ Positive net incomeNet income -$232.0M in FY2025.Why this matters: Does the company actually earn a profit? Sustained losses eventually force it to raise money — diluting you — or take on debt.
-
✗ Positive operating cash flowOperating cash flow -$240.1M (was -$126.2M the prior year).Why this matters: Profit can be an accounting figure; cash from running the business is harder to fake. Negative operating cash flow means the core business consumes cash and must be funded externally.
-
✗ Cash flow backs up reported profitOperating cash flow -$240.1M vs net income -$232.0M.Why this matters: When cash generated exceeds reported earnings, profits are high-quality (not propped up by accruals or one-time items).
-
✗ Return on assets improvingReturn on assets -63.7% vs -31.3% a year ago.Why this matters: Is the company squeezing more profit out of each dollar of assets than last year? Rising = getting more efficient; falling = the opposite.
-
✓ Debt load (vs assets)The filing reports no interest-bearing debt in either year (total assets $364.0M).
-
✓ Short-term liquidity (current ratio)Current ratio 8.88x vs 7.81x a year ago.
-
✗ Share count (dilution)Share count rose 30.1% (0.1M → 0.1M year-over-year).Why this matters: Issuing lots of new shares splits the pie into more pieces, shrinking your slice. Stable or falling share count protects existing owners.
-
· Pricing power (gross margin) (n/a — data not reported; not scored)
-
✗ Sales per asset (asset turnover)Asset turnover 0.09x vs 0.10x a year ago.Why this matters: Asset turnover measures how much revenue each dollar of assets generates. Rising = more productive use of the asset base.
Missing data is never counted as a pass or a fail — it's shown as n/a and excluded from the denominator. Each check compares the company against its own prior year.
Plain English: the company holds about $102M in cash and is burning roughly $240M/year in operations. At that pace, the cash lasts 5 mo before it must raise capital (diluting shareholders), take on debt, or cut spending.
Assumes constant burn and ignores financing/asset sales. For pre-profit biotech and growth companies, this matters more than a DCF — a great drug pipeline is worthless if they run out of money before approval.
EyePoint, Inc. The market is likely discounting the stock due to its declining revenue (-4%/yr over 4yr) and consistent negative net income (profitable 0/5 yrs). The market may be assigning value to potential future drug pipeline catalysts, which are not in the model. The primary quantifiable risk is the negative operating cash flow, which was positive only 1/5 years.
As of 3 months ago
Anatomy of a share
What you're buying per share. Bars are at the same scale so you can see the relative size of revenue, costs, cash flow, and debt — not just read them in a table.
What you actually need to decide
Every stock price is a disagreement. Here's the single thing that must go right for the bulls, the single thing that breaks the thesis, and the concrete signposts to watch so you can update your view as real results arrive.
Why it matters: Compare to current price. Below IV = potentially undervalued. Above IV = priced for growth that must actually happen.
Reference: Model-derived; quality depends on data and assumptions.
Full explanation →, indicating successful commercialization of pipeline assets.
- Announcement of positive Phase 3 clinical trial results
- FDA approval of a new drug candidate
- Quarterly revenue decline exceeding 4%/yr
The trend, in plain numbers (FY2024 → FY2025, latest reported)
Straight from the financial statements — no model, no opinion. For a small or unprofitable company, the direction of these numbers usually tells you more than any single valuation.
- Revenue fell -28% to $31.4M.
- Free cash flow is negative at -$271.3M — the cash burn widened vs last year.
- Still unprofitable at -$232.0M — loss widening.
Nothing was clearly improving year-over-year.
Management & Leadership
Nancy Lurker has served as the President and CEO of EyePoint Pharmaceuticals since 2016. She brings extensive experience in the pharmaceutical and biotech sectors, focusing on ophthalmic treatments. George Elston is the Chief Financial Officer.
What They Make
EyePoint Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative ophthalmic products for serious eye diseases. Their products are primarily used by ophthalmologists to treat patients with chronic eye conditions.
End Markets
Revenue Drivers
Why Is It Priced Like This?
Why Customers Pay
What we use instead: earnings (P/E, EV/EBIT), book value (P/B) — computed from the figures this company does report, shown in the sections below. Those numbers are unaffected by the missing cash-flow data.
This pricing is supported by the declining revenue (-4%/yr over 4yr), consistent negative net income (profitable 0/5 yrs), and negative operating cash flow, indicating ongoing operational challenges. The market may be assigning value to potential future regulatory wins for new drug approvals, which is not in the model.
Business Model & Valuation
How They Make Money
The company funds itself primarily through equity raises and has not paid dividends or engaged in buybacks, consistent with a cash-burning biotech in the growth/re-investment phase.
Growth / Revenue DCF
Negative free cash flow: revenue/margin growth model used - standard FCF DCF is unreliable for companies still scaling.
Show advanced inputs
| Revenue Growth | 2.0% |
What this model does NOT do: this is a consolidated owner-earnings FCF model. Standalone segment assumptions: none. It does not project its revenue segments independently; their combined effect is embedded in the historical revenue and cash-flow trend the model extrapolates. The calculator above can only approximate a segment's impact through the single consolidated growth rate — it cannot model any one line separately. For a true segment-level view, build a separate model from the company's segment disclosures.
Maturity & Competitive Position
Moat Signals
Revenue has been declining at -4%/yr over the past four years, from $37M to $31M.
Geography & Markets
EyePoint Pharmaceuticals is headquartered in the US and primarily serves the US market, though specific geographic revenue breakdowns are not available from current data sources.
Geographic Risks
Market Signals
These are timing signals, not value signals — they describe the stock's recent price behavior, not what the business is worth. Use them for the "the thesis looks good, but is now the moment?" question. Each tile below explains what it's saying.
Why it matters: Short-term contrarian indicator. Extreme readings often precede mean reversion, though not always.
Reference: 30–70 normal · >70 overbought · <30 oversold
Full explanation → (14)53.5NeutralMomentum is balanced — neither overbought nor oversold.
Why it matters: When the fast line crosses above the slow line, short-term momentum is turning up; below, turning down. A timing cue, not a value signal.
Reference: Line above signal = bullish momentum · below = bearish
Full explanation →BullishLine above signalThe fast trend is above the slow trend — short-term momentum is currently upward.
Technicals describe price, not the business. A great company can have a "bearish" tape (a buying chance) and a weak one a "bullish" tape (a trap). Pair these with the valuation and health sections above.
QUALITY
Data Quality & Risk Flags (4 notes — click to expand/collapse)
Guardrail Notes (3)
- FCF negative: revenue/margin growth model projects future cash flows from revenue trajectory.
- Terminal growth (3%) capped to 1.6% (80% of near-term growth 2%).
- Illiquidity discount 7% applied (small/micro-cap — harder to exit, demand a margin).
FINANCIALS
Financial Statements (5-year tables — click to expand)
From EyePoint, Inc.'s SEC filings (EDGAR).
Income (5yr)
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | 31.4M | -232.0M | $-3.17 |
| 2024 | 43.3M | -130.9M | $-2.32 |
| 2023 | 46.0M | -70.8M | $-1.82 |
| 2022 | 41.4M | -102.3M | $-2.74 |
| 2021 | 36.9M | -58.4M | $-2.03 |
Cash Flow (5yr)
| Year | Operating CF | CapEx | − SBC & adj. | Free Cash Flow |
|---|---|---|---|---|
| 2025 | -240.1M | 3.3M | 27.9M | -271.3M |
| 2024 | -126.2M | 4.1M | 36.7M | -167.0M |
| 2023 | 1.9M | 3.5M | 12.1M | -13.7M |
| 2022 | -65.0M | 2.2M | 14.2M | -81.3M |
| 2021 | -50.1M | 156,000 | 7.4M | -57.7M |
How we define FCF: operating cash flow − capital expenditure − stock-based compensation (owner-earnings basis — SBC is a real cost to shareholders even though it's non-cash). Latest year: -240.1M − 3.3M − 27.9M (SBC & adj.) = -271.3M. This is the same owner-earnings FCF definition the valuation model uses, though the DCF's starting value is a projected from revenue × terminal margin, not this single year.
Balance Sheet
| Total Assets | 364.0M |
| Total Liabilities | 57.9M |
| Equity | 306.1M |
Similar companies worth a look
Same sector and industry, similar fundamentals shape. Verify everything yourself — this list is computed mechanically and does not reflect our judgment about whether any of these are a good investment.